Transcription factor Fra-1 induces cholangitis and liver fibrosis

Hepatology

Volumn 53, Issue 4, 2011, Pages 1287-1297

  Kireva, Trayana ^a   Erhardt, Annette ^b   Tiegs, Gisa ^b   Tilg, Herbert ^c   Denk, Helmut ^d   Haybaeck, Johannes ^d   Aigner, Elmar ^e   Moschen, Alexander ^c   Distler, Jörg H ^a   Schett, Georg ^a   Zwerina, Jochen ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b UNIVERSITY OF HAMBURG   (Germany)

^c INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^d MEDICAL UNIVERSITY OF GRAZ   (Austria)

^e MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN; MATRIX METALLOPROTEINASE; MESSENGER RNA; TRANSCRIPTION FACTOR FRA 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; B LYMPHOCYTE; BONE MARROW CELL; CELL INFILTRATION; CELL PROLIFERATION; CHOLANGITIS; DISEASE COURSE; EDITORIAL; FLOW CYTOMETRY; GENE EXPRESSION; GENETIC TRANSCRIPTION; HUMAN; HUMAN TISSUE; IMMUNE SYSTEM; INFLAMMATORY CELL; INFLAMMATORY INFILTRATE; LIVER BIOPSY; LIVER DISEASE; LIVER FIBROSIS; LYMPHOCYTE ACTIVATION; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; TIME;

EID: 79953753357     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.24175     Document Type: Editorial

References (24)

1. Wagner EF. Functions of AP1 (Fos/Jun) in bone development. Ann Rheum Dis 2002; 61( Suppl 2): ii40-42.
2. Jochum W, David JP, Elliott C, Wutz A, Plenk H Jr, Matsuo K, et al. Increased bone formation and osteosclerosis in mice overexpressing the transcription factor Fra-1. Nat Med 2000; 6: 980-984.
3. Belguise K, Kersual N, Galtier F, Chalbos D. FRA-1 expression level regulates proliferation and invasiveness of breast cancer cells. Oncogene 2005; 24: 1434-1444.
4. Eferl R, Wagner EF. AP-1: a double-edged sword in tumorigenesis. Nat Rev Cancer 2003; 3: 859-868.
5. Liu Y, Ludes-Meyers J, Zhang Y, Munoz-Medellin D, Kim HT, Lu C, et al. Inhibition of AP-1 transcription factor causes blockade of multiple signal transduction pathways and inhibits breast cancer growth. Oncogene 2002; 21: 7680-7689.
6. Liu P, Kimmoun E, Legrand A, Sauvanet A, Degott C, Lardeux B, et al. Activation of NF-kappa B, AP-1 and STAT transcription factors is a frequent and early event in human hepatocellular carcinomas. J Hepatol 2002; 37: 63-71.
7. Lazaridis KN, Strazzabosco M, Larusso NF. The cholangiopathies: disorders of biliary epithelia. Gastroenterology 2004; 127: 1565-1577.
8. Reynoso-Paz S, Coppel RL, Mackay IR, Bass NM, Ansari AA, Gershwin ME. The immunobiology of bile and biliary epithelium. HEPATOLOGY 1999; 30: 351-357.
9. Xia X, Demorrow S, Francis H, Glaser S, Alpini G, Marzioni M, et al. Cholangiocyte injury and ductopenic syndromes. Semin Liver Dis 2007; 27: 401-512.
10. Fickert P, Wagner M, Marschall HU, Fuchsbichler A, Zollner G, Tsybrovskyy O, et al. 24-norUrsodeoxycholic acid is superior to ursodeoxycholic acid in the treatment of sclerosing cholangitis in Mdr2 (Abcb4) knockout mice. Gastroenterology 2006; 130: 465-481.
11. Woessner JF Jr. The determination of hydroxyproline in tissue and protein samples containing small proportions of this imino acid. Arch Biochem Biophys 1961; 93: 440-447.
12. Notas G, Kisseleva T, Brenner D. NK and NKT cells in liver injury and fibrosis. Clin Immunol 2009; 130: 16-26.
13. Alpini G, Glaser SS, Ueno Y, Pham L, Podila PV, Caligiuri A, et al. Heterogeneity of the proliferative capacity of rat cholangiocytes after bile duct ligation. Am J Physiol 1998; 274: G767-G775.
14. Pinzani M. Liver fibrosis. Springer Semin Immunopathol 1999; 21: 475-490.
15. Parsons CJ, Takashima M, Rippe RA. Molecular mechanisms of hepatic fibrogenesis. J Gastroenterol Hepatol 2007; 22( Suppl 1): S79-S84.
16. Kanzler S, Lohse AW, Keil A, Henninger J, Dienes HP, Schirmacher P, et al. TGF-beta1 in liver fibrosis: an inducible transgenic mouse model to study liver fibrogenesis. Am J Physiol 1999; 276: G1059-G1068.
17. de Gouville AC, Huet S. Inhibition of ALK5 as a new approach to treat liver fibrotic diseases. Drug News Perspect 2006; 19: 85-90.
18. Moreira RK. Hepatic stellate cells and liver fibrosis. Arch Pathol Lab Med 2007; 131: 1728-1734.
19. Hieshima K, Imai T, Baba M, Shoudai K, Ishizuka K, Nakagawa T, et al. A novel human CC chemokine PARC that is most homologous to macrophage-inflammatory protein-1 alpha/LD78 alpha and chemotactic for T lymphocytes, but not for monocytes. J Immunol 1997; 159: 1140-1149.
20. Nakken KE, Nygard S, Haaland TK, Berge KE, Odegaard A, Labori KJ, et al. Gene expression profiles reflect sclerosing cholangitis activity in abcb4 (-/-) mice. Scand J Gastroenterol 2009; 44: 211-218.
21. Roos RS, Loetscher M, Legler DF, Clark-Lewis I, Baggiolini M, Moser B. Identification of CCR8, the receptor for the human CC chemokine I-309. J Biol Chem 1997; 272: 17251-17254.
22. Proost P, Wuyts A, van Damme J. The role of chemokines in inflammation. Int J Clin Lab Res 1996; 26: 211-223.
23. Persson T, Monsef N, Andersson P, Bjartell A, Malm J, Calafat J, et al. Expression of the neutrophil-activating CXC chemokine ENA-78/CXCL5 by human eosinophils. Clin Exp Allergy 2003; 33: 531-537.
24. Selmi C, Lleo A, Pasini S, Zuin M, Gershwin ME. Innate immunity and primary biliary cirrhosis. Curr Mol Med 2009; 9: 45-51.